Viking Therapeutics Just Soared 120% on Optimism About Its Weight Loss Candidate. Too Late to Buy?The Motley Fool • 02/29/24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common StockPRNewsWire • 02/29/24
Viking Therapeutics: Impressive Obesity Data Puts VK2735 As The Lead Asset (Rating Upgrade)Seeking Alpha • 02/28/24
Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug crazeMarket Watch • 02/27/24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with ObesityPRNewsWire • 02/27/24